IceCure Medical yesterday said it received Israeli AMAR authorization to use its freezing technology in specific indications. The approval will allow the Israel-based company to use the technology to freeze benign and malignant tumors, including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. Get the full story on our sister site, MassDevice.
The post IceCure Medical wins Israeli AMAR approval for tumor freezing technology appeared first on Medical Design and Outsourcing.